Inflammatory cues acting on the adult intestinal stem cells and the early onset of cancer (Review)

International Journal of Oncology

Volumn 45, Issue 3, 2014, Pages 959-968

  De Lerma Barbaro, A ^a   Perletti, Gianpaolo ^a,b   Bonapace, I M ^a   Monti, E ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Cancer stem cells; Carcinogenesis; Chronic inflammation; Colon cancer; Paneth cells

Indexed keywords

ADULT STEM CELL; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER STEM CELL; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CHRONIC INFLAMMATION; COLON CANCER; COLON CARCINOGENESIS; COLORECTAL CANCER; DEVELOPMENTAL BIOLOGY; DISEASE ASSOCIATION; HOMEOSTASIS; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE CANCER; INTESTINE CELL; INTESTINE CRYPT; INTESTINE EPITHELIUM; INTESTINE STEM CELL; INTRACELLULAR SIGNALING; NONHUMAN; PANETH CELL; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; REVIEW; STEM CELL NICHE; TRANSGENICS; CELL MOTION; CELL TRANSFORMATION; COLITIS; COLORECTAL TUMOR; CYTOLOGY; IMMUNOLOGY; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ADULT STEM CELLS; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; COLITIS; COLORECTAL NEOPLASMS; HUMANS; INTESTINAL MUCOSA; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; STEM CELL NICHE;

EID: 84904387217     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2490     Document Type: Review

References (103)

1. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
2. Thun MJ, Henley SJ and Gansler T: Inflammation and cancer: an epidemiological perspective. Novartis Found Symp 256: 6-21, 2004.
3. Allavena P, Garlanda C, Borrello MG, Sica A and Mantovani A: Pathways connecting inflammation and cancer. Curr Opin Genet Dev 18: 3-10, 2008. (Pubitemid 351694444)
4. Colotta F, Allavena P, Sica A, Garlanda C and Mantovani A: Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30: 1073-1081, 2009.
5. Grivennikov SI, Greten FR and Karin M: Immunity, inflammation, and cancer. Cell 140: 883-899, 2010.
6. Trinchieri G: Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu Rev Immunol 30: 677-706, 2012.
7. Boland C, Luciani M, Gasche C and Goel A: Infection, inflammation, and gastrointestinal cancer. Gut 54: 1321-1331, 2005. (Pubitemid 41192496)
8. Potten CS, Gandara R, Mahida YR, Loeffler M and Wright NA: The stem cells of small intestinal crypts: Where are they? Cell Prolif 42: 731-750, 2009.
9. Barker N, Ridgway RA, van Es JH, et al: Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457: 608-611, 2009.
10. Sangiorgi E and Capecchi MR: Bmi1 is expressed in vivo in intestinal stem cells. Nat Genet 40: 915-920, 2008. (Pubitemid 351913652)
11. Dyson JK and Rutter MD: Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk? World J Gastroenterol 18: 3839-3848, 2012.
12. Eaden JA, Abrams KR and Mayberry JF: The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48: 526-535, 2001. (Pubitemid 32234798)
13. Canavan C, Abrams KR and Mayberry J: Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther 23: 1097-1104, 2006. (Pubitemid 43779348)
14. Rubio CA, Befrits R, Ljung T, Jaramillo E and Slezak P: Colorectal carcinoma in ulcerative colitis is decreasing in Scandinavian countries. Anticancer Res 21: 2921-2924, 2001. (Pubitemid 33051152)
15. Jess T, Loftus EV Jr, Velayos FS, et al: Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted county, Minnesota. Gastroenterology 130: 1039-1046, 2006.
16. Winther KV, Jess T, Langholz E, Munkholm P and Binder V: Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2: 1088-1095, 2004. (Pubitemid 40037640)
17. Loftus EV Jr: Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis. Gastroenterol Clin North Am 35: 517-531, 2006.
18. Ullman TA and Itzkowitz SH: Intestinal inflammation and cancer. Gastroenterology 140: 1807-1816, 2011.
19. Harpaz N and Polydorides AD: Colorectal dysplasia in chronic inflammatory bowel disease: pathology, clinical implications, and pathogenesis. Arch Pathol Lab Med 134: 876-895, 2010.
20. Riddell RH, Goldman H, Ransohoff DF, et al: Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 14: 931-968, 1983.
21. Friedlich MS, Guindi M and Stern HS: The management of dysplasia associated with ulcerative colitis: colectomy versus continued surveillance. Can J Surg 4: 212-214, 2004. (Pubitemid 39164376)
22. Kulaylat MN and Dayton MT: Ulcerative colitis and cancer. J Surg Oncol 101: 706-712, 2010.
23. Grivennikov SI and Karin M: Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev 20: 65-71, 2010.
24. Grivennikov S: Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol 35: 229-244, 2013.
25. Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
26. Xie J and Itzkowitz SH: Cancer in inflammatory bowel disease. World J Gastroenterol 14: 378-389, 2008. (Pubitemid 351320846)
27. Terzić J, Grivennikov S, Karin E and Karin M: Inflammation and colon cancer. Gastroenterology 138: 2101-2114, 2010.
28. Itzkowitz SH and Harpaz N: Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 126: 1634-1648, 2004. (Pubitemid 38649879)
29. Taylor BA, Pemberton JH, Carpenter HA, et al: Dysplasia in chronic ulcerative colitis: implications for colonoscopic surveillance. Dis Colon Rectum 35: 950-956, 1992.
30. Gorfine SR, Bauer JJ, Harris MT and Kreel I: Dysplasia complicating chronic ulcerative colitis: is immediate colectomy warranted? Dis Colon Rectum 43: 1575-1581, 2000.
31. Bernstein CN, Shanahan F and Weinstein WM: Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 343: 71-74, 1994. (Pubitemid 24019346)
32. Rutter MD, Saunders BP, Wilkinson KH, et al: Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 130: 1030-1038, 2006.
33. Connell WR, Lennard-Jones JE, Williams CB, Talbot IC, Price AB and Wilkinson KH: Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 107: 934-944, 1994. (Pubitemid 24294554)
34. Melville DM, Jass JR, Morson BC, et al: Observer study of the grading of dysplasia in ulcerative colitis: comparison with clinical outcome. Hum Pathol 20: 1008-1014, 1989. (Pubitemid 19267907)
35. Sjöqvist U: Dysplasia in ulcerative colitis - clinical consequences? Langenbecks Arch Surg 389: 354-360, 2004.
36. Deans C and Wigmore SJ: Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care 8: 265-269, 2005. (Pubitemid 40586184)
37. Philip M, Rowley DA and Schreiber H: Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 14: 433-439, 2004. (Pubitemid 39360991)
38. DeNardo DG, Johansson M and Coussens LM: Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev 27: 11-18, 2008.
39. Kalluri R: EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest 119: 1417-1419, 2009.
40. Luo Y, Yu M and Grady WM: Field cancerization in the colon: a role for aberrant DNA methylation? Gastroenterol Rep 2: 16-20, 2014 (Epub ahead of print).
41. Kaler P, Godasi BN, Augenlicht L and Klampfer L: The NFkappaB/AKT- dependent induction of Wnt signaling in colon cancer cells by macrophages and IL-1beta. Cancer Microenviron 2: 69-80, 2009.
42. Lee G, Goretsky T, Managlia E, et al: Phosphoinositide 3-kinase signaling mediates beta-catenin activation in intestinal epithelial stem and progenitor cells in colitis. Gastroenterology 139: 869-881, 2010.
43. Oguma K, Oshima H, Aoki M, et al: Activated macrophages promote Wnt signalling through tumor necrosis factor-alpha in gastric tumor cells. EMBO J 27: 1671-1681, 2008.
44. Castellone MD, Teramoto H, Williams BO, Druey KM and Gutkind JS: Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 310: 1504-1510, 2005. (Pubitemid 41746348)
45. Corvinus FM, Orth C, Moriggl R, et al: Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 7: 545-555, 2005. (Pubitemid 40967755)
46. Yu H, Kortylewski M and Pardoll D: Crosstalk between cancer and immune cells: role of STAT3 in the tumor microenvironment. Nature Rev Immunol 7: 41-51, 2007. (Pubitemid 46020826)
47. Van Immerseel F, Ducatelle R, De Vos M, et al: Butyric acid-producing anaerobic bacteria as a novel probiotic treatment approach for inflammatory bowel disease. J Med Microbiol 59: 141-143, 2010.
48. Van der Sluis M, De Koning BA, De Bruijn AC, et al: Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 131: 117-129, 2006. (Pubitemid 44015753)
49. Velcich A, Yang W, Heyer J, et al: Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 295: 1726-1729, 2002. (Pubitemid 34202910)
50. Petersson J, Schreiber O, Hansson GC, et al: Importance and regulation of the colonic mucus barrier in a mouse model of colitis. Am J Physiol Gastrointest Liver Physiol 300: G327-G333, 2011.
51. Arthur JC, Perez-Chanona E, Mühlbauer M, et al: Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338: 120-123, 2012.
52. Sharma S, Kelly TK and Jones PA: Epigenetics in cancer. Carcinogenesis 31: 27-36, 2010.
53. Suvà ML, Riggi N and Bernstein BE: Epigenetic reprogramming in cancer. Science 339: 1567-1570, 2013.
54. Chiba T, Marusawa H and Ushijima T: Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology 143: 550-563, 2012.
55. Niwa T and Ushijima T: Induction of epigenetic alterations by chronic inflammation and its significance on carcinogenesis. Adv Genet 71: 41-56, 2010.
56. Robertson KD: DNA methylation and human disease. Nat Rev Genet 6: 597-610, 2005.
57. Hahn MA, Hahn T, Lee DH, et al: Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. Cancer Res 68: 10280-10289, 2008.
58. Cirri P and Chiarugi P: Cancer-associated-fibroblasts and tumor cells: a diabolic liaison driving cancer progression. Cancer Metastasis Rev 31: 195-208, 2012.
59. Achyut BR, Bader DA, Robles AI, et al: Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-β signaling. PLoS Genet 9: e1003251, 2013.
60. El-Omar EM, Carrington M, Chow WH, et al: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404: 398-402, 2000. (Pubitemid 30164342)
61. El-Omar EM, Carrington M, Chow WH, et al: The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer. Nature 412: 99, 2001.
62. Chan AO, Chu KM, Huang C, et al: Association between Helicobacter pylori infection and interleukin 1 beta polymorphism predispose to CpG island methylation in gastric cancer. Gut 56: 595-597, 2007. (Pubitemid 46580521)
63. Niwa T, Tsukamoto T, Toyoda T, et al: Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res 70: 1430-1440, 2010.
64. McLaughlan JM, Seth R, Vautier G, et al: Interleukin-8 and inducible nitric oxide synthase mRNA levels in inflammatory bowel disease at first presentation. J Pathol 181: 87-92, 1997. (Pubitemid 27099779)
65. Yoshida T, Yamashita S, Takamura-Enya T, et al: Alu and Satα hypomethylation in Helicobacter pylori-infected gastric mucosae. Int J Cancer 128: 33-39, 2011.
66. Semenza G: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
67. Giles RH, Lolkema MP, Snijckers CM, et al: Interplay between VHL/HIF1alpha and Wnt/beta-catenin pathways during colorectal tumorigenesis. Oncogene 25: 3065-3070, 2006. (Pubitemid 43780471)
68. Shah YM, Ito S, Morimura K, Chen C, et al: Hypoxia-inducible factor augments experimental colitis through an MIF-dependent inflammatory signaling cascade. Gastroenterology 134: 2036-2048, 2008.
69. Imtiyaz HZ, Williams EP, Hickey MM, Patel SA, et al: Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation. J Clin Invest 120: 2699-2714, 2010.
70. Chaturvedi MM, Sung B, Yadav VR, Kannappan R and Aggarwal BB: NF-κB addiction and its role in cancer: 'one size does not fit all'. Oncogene 30: 1615-1630, 2011.
71. Colgan SP, Curtis VF and Campbell EL: The inflammatory tissue microenvironment in IBD. Inflamm Bowel Dis 19: 2238-2244, 2013.
72. Colgan SP and Taylor CT: Hypoxia: an alarm signal during intestinal inflammation. Nat Rev Gastroenterol Hepatol 7: 281-287, 2010.
73. Clambey ET, McNamee EN, Westrich JA, et al: Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc Natl Acad Sci USA 109: E2784-E2793, 2012.
74. Olaru AV, Selaru FM, Mori Y, et al: Dynamic changes in the expression of MicroRNA-31 during inflammatory bowel disease-associated neoplastic transformation. Inflamm Bowel Dis 17: 221-231, 2011.
75. Gillies RJ and Gatenby RA: Hypoxia and adaptive landscapes in the evolution of carcinogenesis. Cancer Metastasis Rev 26: 311-317, 2007. (Pubitemid 47101668)
76. Covello KL, Kehler J, Yu H, et al: HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 20: 557-570, 2006. (Pubitemid 43345322)
77. Edwards RA, Witherspoon M, Wang K, et al: Epigenetic repression of DNA mismatch repair by inflammation and hypoxia in inflammatory bowel disease-associated colorectal cancer. Cancer Res 69: 6423-6429, 2009.
78. Clevers H and Batlle E: SnapShot: the intestinal crypt. Cell 152: 1198-1198, 2013.
79. Barker N, van Es JH, Kuipers J, et al: Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449: 1003-1007, 2007. (Pubitemid 350014593)
80. Barker N, van de Wetering M and Clevers H: The intestinal stem cell. Genes Dev 22: 1856-1864, 2008. (Pubitemid 352008634)
81. Li L and Clevers H: Coexistence of quiescent and active adult stem cells in mammals. Science 327: 542-545, 2010.
82. Shih IM, Wang TL, Traverso G, et al: Top-down morphogenesis of colorectal tumors. Proc Natl Acad Sci USA 98: 2640-2645, 2001. (Pubitemid 32209535)
83. Preston SL, Wong WM, Chan AO, et al: Bottom-up histogenesis of colorectal adenomas: origin in the monocryptal adenoma and initial expansion by crypt fission. Cancer Res 63: 3819-3825, 2003. (Pubitemid 36793072)
84. Ward RJ and Dirks PB: Cancer stem cells: at the headwaters of tumor development. Annu Rev Pathol 2: 175-189, 2007. (Pubitemid 46448063)
85. Scheel C and Weinberg RA: Phenotypic plasticity and epithelial- mesenchymal transitions in cancer and normal stem cells? Int J Cancer 129: 2310-2314, 2011.
86. Roskams T: Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 25: 3818-3822, 2006.
87. El Marjou F, Janssen KP, Chang BH, et al: Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis 39: 186-193, 2004. (Pubitemid 39079517)
88. Haigis KM, Hoff PD, White A, Shoemaker AR, Halberg RB and Dove WF: Tumor regionality in the mouse intestine reflects the mechanism of loss of Apc function. Proc Natl Acad Sci USA 101: 9769-9773, 2004. (Pubitemid 38869311)
89. Shaked H, Hofseth LJ, Chumanevich A, et al: Chronic epithelial NF-kappaB activation accelerates APC loss and intestinal tumor initiation through iNOS up-regulation. Proc Natl Acad Sci USA 109: 14007-14012, 2012.
90. Kanneganti M, Mino-Kenudson M and Mizoguchi E: Animal models of colitis-associated carcinogenesis. J Biomed Biotechnol 2011: 342637, 2011.
91. Rowlatt C, Franks LM, Sheriff MU and Chesterman FC: Naturally occurring tumors and other lesions of the digestive tract in untreated C57BL mice. J Natl Cancer Inst 43: 1353-1364, 1969.
92. Preston SL, Leedham SJ, Oukrif D, et al: The development of duodenal microadenomas in FAP patients: the human correlate of the Min mouse. J Pathol 214: 294-301, 2008. (Pubitemid 351212384)
93. Sato T, van Es JH, Snippert HJ, et al: Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature 469: 415-418, 2011.
94. Clevers HC and Bevins CL: Paneth cells: maestros of the small intestinal crypts. Annu Rev Physiol 75: 289-311, 2013.
95. Tu S, Bhagat G, Cui G, et al: Overexpression of interleukin 1β induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 14: 408-419, 2008.
96. Sturlan S, Oberhuber G, Beinhauer BG, et al: Interleukin-10-deficient mice and inflammatory bowel disease associated cancer development. Carcinogenesis 22: 665-671, 2001. (Pubitemid 32288669)
97. Lala S, Ogura Y, Osborne C, et al: Crohn's disease and the NOD2 gene: a role for Paneth cells. Gastroenterology 125: 47-57, 2003. (Pubitemid 36799106)
98. Medema JP and Vermeulen L: Microenvironmental regulation of stem cells in intestinal homeostasis and cancer. Nature 474: 318-326, 2011.
99. Scadden DT: The stem-cell niche as an entity of action. Nature 441: 1075-1079, 2006.
100. Barcellos-Hoff MH, Lyden D and Wang TC: The evolution of the cancer niche during multistage carcinogenesis. Nat Rev Cancer 13: 511-518, 2013.
101. Kemper K, Prasetyanti PR, De Lau W, Rodermond H, Clevers H and Medema JP: Monoclonal antibodies against Lgr5 identify human colorectal cancer stem cells. Stem Cells 30: 2378-2386, 2012.
102. Vaishnava S, Behrendt CL, Ismail AS, Eckmann L and Hooper LV: Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface. Proc Natl Acad Sci USA 105: 20858-20863, 2008.
103. Gum JR Jr, Hicks JW, Gillespie AM, et al: Goblet cell-specific expression mediated by the MUC2 mucin gene promoter in the intestine of transgenic mice. Am J Physiol 276: G666-G676, 1999. (Pubitemid 29157432)